Abrignani Sergio

Chief Scientific Officer

Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells.
D’Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G, Abrignani S.
Eur J Immunol. 2000 Jun;30(6):1544-50.

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.
Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S.
J Virol. 2000 Aug;74(15):6885-92.

Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C.
Valiante NM, D’Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, Wack A, Abrignani S.
Immunol Rev. 2000 Apr;174:77-89. Review.

Structure-function analysis of hepatitis C virus envelope-CD81 binding.
Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, Abrignani S, Grandi G.
J Virol. 2000 May;74(10):4824-30.

Perspectives for a vaccine against hepatitis C virus.
Abrignani S, Houghton M, Hsu HH.
J Hepatol. 1999;31 Suppl 1:259-63. Review.

Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice.
Toneatto S, Finco O, van der Putten H, Abrignani S, Annunziata P.
AIDS. 1999 Dec 3;13(17):2343-8.

Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors.
Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, Abrignani S, Sette A, Barnaba V.
J Immunol. 1999 Jun 1;162(11):6681-9.

Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis.
Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V, Abrignani S.
Eur J Immunol. 1998 Nov;28(11):3448-55.

Binding of hepatitis C virus to CD81.
Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S.
Science. 1998 Oct 30;282(5390):938-41.

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.
Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, Abrignani S, Miyamura T.
Hepatology. 1998 Oct;28(4):1117-20.

Perspectives for a hepatitis C virus vaccine.
Abrignani S, Rosa D.
Clin Diagn Virol. 1998 Jul 15;10(2-3):181-5. Review.

Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.
Habersetzer F, Fournillier A, Dubuisson J, Rosa D, Abrignani S, Wychowski C, Nakano I, Trépo C, Desgranges C, Inchauspé G.
Virology. 1998 Sep 15;249(1):32-41.

Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.
Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, Bugli F, Solforosi L, Abrignani S, Varaldo PE, Fadda G, Clementi M.
Hepatology. 1998 Sep;28(3):810-4.

Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid.
Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kocken C, Thomas A, Abrignani S, Grandi G.
Eur J Immunol. 1998 Apr;28(4):1225-32.

Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis.
Abrignani S.
Dev Biol Stand. 1998;92:191-4.

INGM researches are supported by